Opportunity Outlook on the Global Benign Prostatic Hyperplasia Therapeutics Market to 2025: High Market Potential in Untapped Emerging Economies - ResearchAndMarkets.com
Aug. 24, 2018
DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients.
Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market.
List of Key Players ProfiledAbbott Laboratories Allergan PLC Astellas Pharma Inc. Boehringer Ingelheim Pharma GmbH & Co. KG Eli Lilly and Company GlaxoSmithKline PLC Merck & Co. Inc. Pfizer Inc. Sanofi Teva Pharmaceutical Industries Limited
Key Topics Covered
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutic Class
Chapter 5: Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
Chapter 6: Benign Prostatic Hyperplasia Therapeutics Market, by Region
Chapter 7: Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/hcsnvd/opportunity?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005086/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Prostate Cancer Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/24/2018 04:57 AM/DISC: 08/24/2018 04:57 AM